A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
A phase 1/2 trial of YL201, Ivonescimab in non-small-cell lung cancer and small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
Overview
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07208773 by MediLink Therapeutics (Suzhou) Co., Ltd., with 260 participants planned, started 2025-10-29 and due to reach its primary completion in 2027-01. Interventions recorded: YL201, Ivonescimab. Conditions listed: Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
Shares YL201, MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）
Shares YL201, MediLink Therapeutics, Non-small-cell lung cancer.
- TrialA Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
Shares YL201, MediLink Therapeutics.
- TrialA Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)
Shares YL201, MediLink Therapeutics.
- TrialA Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Shares YL201, MediLink Therapeutics.
- TrialA Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Shares MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of YL202 in Patients With Advanced Solid Tumors
Shares MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.